SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused
on neurological and endocrine related disorders, announced that
David-Alexandre "DA" Gros M.D. has joined the executive management
team as President and Chief Operating Officer.
"Neurocrine is very pleased to welcome Dr. Gros as our
President and Chief Operating Officer as we move forward with our
transformation into a commercial entity," said Kevin Gorman,
Chief Executive Officer of Neurocrine Biosciences. "DA's breadth of
experience across all aspects of drug development and
commercialization will be of critical importance as we enter this
period of rapid growth. He will also be instrumental in executing
on our long-range strategic plans. We are excited to have him join
our team."
"Neurocrine is a remarkably innovative company, leading the
development of novel therapeutics to address major unmet needs in
neurological and endocrine disorders," said Dr. Gros. "I am very
excited to join the company during this pivotal growth phase and
look forward to contributing to Neurocrine's continued
success."
Dr. Gros has extensive experience in developing and
executing bio-pharmaceutical growth strategies. He joins Neurocrine
from Alnylam Pharmaceuticals where he served as Senior Vice
President, Chief Business Officer and was a member of the
Management Board. His responsibilities included strategy, finance,
business development, communications, investor relations, and
shared services. Prior to Alnylam, as Executive Vice President and
Chief Strategy Officer at Sanofi, where he was a member of the
Executive Committee, Dr. Gros' responsibilities included corporate
strategy, business development and licensing, mergers and
acquisitions, alliance management, and structured investments,
including the corporate venture fund which he re-launched. Before
Sanofi, Dr. Gros held management positions of increasing
responsibility with a focus on biotechnology and pharmaceuticals in
investment banking at Centerview Partners and Merrill
Lynch, and in consulting at McKinsey & Company. Dr.
Gros holds an M.D. from The Johns
Hopkins University School of Medicine, an M.B.A.
from Harvard Business School, and a B.A. from Dartmouth
College.
Neurocrine also announced the grant of an inducement award to
Dr. Gros pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
In connection with his employment by Neurocrine, Dr. Gros will be
granted an inducement award consisting of a stock option to
purchase 350,000 shares of Neurocrine common stock. The stock
option will vest over a period of four years, with 25% vesting on
the first anniversary of its grant date and the balance vesting
each month over the remaining three years. This award is subject to
the terms and conditions of Neurocrine's Inducement Plan. The award
will be effective on February 1,
2017, which is the first day of the first calendar month
following the commencement of Dr. Gros' employment with Neurocrine,
and will have an exercise price equal to the closing price of
Neurocrine's common stock on the NASDAQ Global Select Market on
that date. The award was granted as an inducement material to Dr.
Gros' employment pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules.
About Neurocrine Biosciences
Neurocrine Biosciences,
Inc. discovers and develops innovative and life-changing
pharmaceuticals in diseases with high unmet medical needs through
its novel R&D platform, focused on neurological and endocrine
based diseases and disorders. The Company's two programs are
elagolix, a gonadotropin-releasing hormone antagonist in Phase III
development for women's health that is partnered with AbbVie Inc.,
and INGREZZATM, a vesicular monoamine transporter 2
inhibitor for which an NDA has been filed with the FDA for the
treatment of tardive dyskinesia, and is in Phase II development for
patients with Tourette syndrome. Neurocrine plans to commercialize
INGREZZA in the United States upon
approval of the NDA by the FDA.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
In addition to historical facts, this press release may
contain forward-looking statements that involve a number of risks
and uncertainties. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with Neurocrine's business and finances in general, INGREZZA
development and commercialization, the Company's R & D pipeline
and the Company overall. Specifically, the risks and uncertainties
the Company faces include risks that INGREZZA or the Company's
other product candidates may not obtain regulatory approval or that
the U.S. Food and Drug Administration or regulatory authorities
outside the U.S. may make adverse decisions regarding INGREZZA or
the Company's other product candidates; risks that clinical
development activities may not be completed on time or at all;
risks that clinical development activities may be delayed for
regulatory or other reasons, may not be successful, or replicate
previous clinical trial results, may fail to demonstrate that our
product candidates are safe and effective, or may not be predictive
of real-world results or of results in subsequent clinical trials;
risks that the Company's product candidates may be precluded from
commercialization by the proprietary rights of third parties, or
have unintended side effects, adverse reactions or incidents of
misuse; risks associated with the Company's dependence on third
parties for development, manufacturing and marketing activities;
risks that the Company's research programs will not identify
pre-clinical candidates for further development; risks that
the Company will be unable to raise additional funding required to
complete development of all of its product candidates; risks and
uncertainties relating to competitive products and technological
changes that may limit demand for the Company's products; and other
risks described in the Company's quarterly report on Form 10-Q for
the quarter ended September 30, 2016.
Neurocrine disclaims any obligation to update the statements
contained in this press release after the date hereof.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-the-appointment-of-david-alexandre-gros-md-president-and-chief-operating-officer-300386844.html
SOURCE Neurocrine Biosciences, Inc.